Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

Thu, 29th Jul 2021 17:10

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Hargreaves Lansdown PLC - Bristol-based wealth management platform - Chief Financial Officer Philip Johnson will step down for "personal reasons" after a transition. HL now will search for a successor.

----------

Pearson PLC - London-based education publisher - Elizabeth Corley will step down as non-executive director after being named the next chair of asset manager Schroders PLC. Corley will join the Schroders board on September 1, at which time she will step down as chair of the Pearson board's Remuneration Committee. Corley will step down from the Pearson board itself before becoming assuming the Schroders chair after the Schroders annual general meeting on April 28, 2022. Until 2016, Corley was chief executive of Allianz Global Investors. She previously was a consulting partner for Merrill Lynch Investment Managers and Coopers & Lybrand.

----------

Jupiter Fund Management PLC - London-based long-term, active investor - Hires Dale Murray as independent non-executive director, starting September 1. Murray co-founded mobile telecommunications software firm Omega Logic and led the business after its takeover by First Data Corp, before becoming an angel investor in the digital sector.

----------

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Hires David Allmond as chief executive officer and director, starting October 18 and replacing Graham Mullis, who will retire after 13 years with the company and a predecessor. Allmond is chief business officer at fellow AIM listing Amryt Pharma PLC.

----------

Stock Spirits Group PLC - branded spirits and liqueurs in Central and Eastern Europe and Italy - Hires Juliette Stacey as independent non-executive director. Stacey is senior independent director of pub chain Fuller, Smith & Turner PLC and as an executive was chief operating officer, Commercial UK & Europe, for estate agent Savills PLC.

----------

C&C Group PLC - Dublin-based beer, cider, wine, spirits and soft drinks - Chief Operating Officer Andrea Pozzi will step down from the board on September 1 but will remain with C&C to manage its GB businesses trading under the Tennent's brand. The executive director role of COO will be divided among other executive directors. Meanwhile, Jim Clerkin will step down as non-executive director on October 27 after four years to focus on work responsibilities in the US.

----------

IQE PLC - Cardiff-based semiconductor wafers and materials - Hires Victoria Hull as non-executive director, starting on Sunday. Hull is senior independent director of FTSE 250-constituent Ultra Electronics Holdings PLC and also is on the boards of Network International Holdings PLC and Alphawave IP Group PLC.

----------

ADM Energy PLC - investor with producing interests in Nigeria - Hires Oliver Andrews as non-executive chair, starting on Monday next week. Andrews replaces Peter Francis, who will step down from the board on Monday for "personal circumstances". Andrews was chief investment officer at natural resources and infrastructure investor Africa Finance Corp.

----------

Seplat Energy PLC - Hires Emma FitzGerald as independent non-executive director, starting August 1 and replacing Mark Malloch-Brown. FitzGerald is a former executive at oil major Royal Dutch Shell PLC, power distributor National Grid PLC and water works Severn Trent PLC.

----------

TR European Growth Trust PLC - Janus Henderson-managed fund that seeks capital growth by investing in smaller and medium sized in Europe outside the UK - Promotes Simona Heidempergher to senior independent director, starting immediately. Heidempergher has been one of the trust's European-based directors since 2014. She is managing director of Merifin Capital and lead independent director of Milan-listed Aquafil Spa.

----------

Argo Blockchain PLC - London-based cryptocurrency mining - Refreshes board by hiring Colleen Sullivan, Maria Perrella, and Sarah Gow as independent non-executive directors, and adding Alex Appleton as executive director. Meanwhile, Peter Wall will be interim chair as well as CEO until a new chair is found. The new appointments replace Ian Macleod as executive chair and James Savage and Marco D'Attanasio as non-executive directors. Sullivan is CEO of CMT Digital, part of CMT Group, specialising in crypto-asset trading and blockchain technology investments. Perrella was CFO of MDA, a Canadian space mission partner. Gow spent 11 years at Citigroup Asset Management, serving as director of Global Operations in New York and head of Operations in London. Appleton has been Argo Blockchain's finance director since September last year.

----------

Anglesey Mining PLC - developing Parys Mountain copper-zinc-lead deposit in northern Wales - Hires Jo Battershill as chief executive, starting on Sunday. Battershill has been a broker at Canaccord Genuity Group Inc and UBS Group AG for the past 13 years, ending as head of Sales & Distribution of Australian equities in the Europe, Middle East and Africa region for Canaccord. He previously had worked in mining operations at Western Mining Corp in Australia. Battershill replaces Bill Hooley, who moves to deputy chair, also from Sunday. Speaking to two other "senior minerals industry professionals" to become non-executive directors. Anglesey will hold its AGM on September 30 but its results for the financial year that ended March 31 will be delayed by up to two months in order to complete the audit. Anglesey says it knows of no material issues with the accounts, and the delay is due to the difficulties caused by the Covid-19 pandemic.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 May 2018 13:13

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is

Read more
15 Mar 2018 14:15

Amryt 2017 Revenue Soars On Lojuxta Sales As New In-Licence Sealed

LONDON (Alliance News) - Amryt Pharma PLC said Thursday it has signed an in-licence agreement for a gene therapy platform, with the company making a "very start in for to

Read more
15 Mar 2018 05:25

UK Stocks-Factors to watch on March 15

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2 points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to

Read more
8 Mar 2018 15:39

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 9 March SIGFull Year ResultsInmarsatFull Year ResultsGVC Year 12

Read more
6 Feb 2017 09:23

Amryt Pharma Gets Positive Study Results For Possible Acromegaly Drug

Read more
2 Dec 2016 08:07

Amryt Pharma secures €20m loan from European Investment Bank

(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi

Read more
7 Nov 2016 12:19

Amryt Pharma's drug compound gains FDA approval

(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg

Read more
13 Sep 2016 16:10

Amryt Pharma positive about drug developments

(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock

Read more
9 Jun 2016 09:55

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

Read more
19 Apr 2016 12:05

Amryt Pharma reverses onto AIM to advance orphan drug strategy

(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com

Read more
19 Apr 2016 08:52

Amryt Pharma Starts Trading After Fastnet Reverse Takeover (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.